Viking Therapeutics Set to Showcase Innovations at Investor Events
Viking Therapeutics Set to Showcase Innovations at Investor Events
Viking Therapeutics, Inc. (NASDAQ: VKTX), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for metabolic and endocrine disorders, has exciting news regarding its participation in several upcoming investor conferences. These gatherings are excellent opportunities for Viking to highlight its advancements and connect with potential investors.
Investor Conference Details
The company’s participation includes several high-profile conferences designed to foster dialogue with the investment community. Here are the key details:
Truist Healthcare Conference
Details: Management will engage in a fireside chat and conduct one-on-one meetings.
Conference Date: Scheduled for November 7, 2024.
Fireside Chat Timing: 12:30 – 1:00 p.m. Eastern on Thursday.
Location: New York.
UBS Global Healthcare Conference
Details: Management will engage in one-on-one meetings.
Conference Dates: Set for November 11-14, 2024.
Location: Rancho Palos Verdes.
Stifel 2024 Healthcare Conference
Details: Management will present the company’s latest developments and participate in one-on-one meetings.
Conference Dates: November 18-19, 2024.
Presentation Timing: 8:35 – 9:05 a.m. Eastern on November 19.
Location: New York.
Jefferies London Healthcare Conference 2024
Details: Viking management will present the company’s initiatives and hold one-on-one meetings.
Conference Dates: November 19-21, 2024.
Presentation Timing: 9:00 – 9:25 a.m. GMT on November 21.
Location: London.
What to Expect from the Presentations
During these conferences, Viking Therapeutics aims to provide insights into its promising pipeline of therapies targeting various metabolic and endocrine disorders. One standout candidate is VK2735, a dual agonist for GLP-1 and GIP receptors. Current trials have shown it to be safe and effective, paving the way for potential market introduction.
The company is also progressing with VK2809, a selective thyroid hormone receptor beta agonist aimed at treating conditions like NASH and NAFLD. This drug has demonstrated significant efficacy in trials, indicating a bright future for its market presence.
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. specializes in developing first-in-class and best-in-class therapies focused on metabolic and endocrine health. It currently has three compounds undergoing clinical trials, leveraging its extensive expertise in metabolism to innovate and improve patient outcomes. Each clinical program is backed by solid research, showcasing the company's commitment to advancing treatment options.
Frequently Asked Questions
What type of company is Viking Therapeutics?
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic and endocrine disorders.
Which major investor conferences will Viking attend?
Viking will participate in the Truist Healthcare Conference, UBS Global Healthcare Conference, Stifel 2024 Healthcare Conference, and Jefferies London Healthcare Conference.
What therapies is Viking currently developing?
Viking is developing several innovative therapies including VK2735 for metabolic disorders and VK2809 for lipid and metabolic disorders.
When will the conferences take place?
The upcoming conferences are scheduled from November 7 to November 21, 2024.
How can I find more information about Viking Therapeutics?
For detailed insights on Viking Therapeutics and their ongoing projects, please visit their official website.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Recent Articles
- Ammo Inc. Faces Market Challenges with Stock at New Low
- HitPaw VikPea Elevates Video Enhancement with Exciting Features
- Bicycle Therapeutics Boosts Target Price Amid Pipeline Advances
- Jazz Pharmaceuticals Unveils Key Findings on Xywav for Sleep Disorders
- Foresight Autonomous Holdings Faces Challenges Amid New Low
- Hilb Group Secures Major Debt Refinancing for Future Growth
- RF Acquisition Corp Hits Milestone with 52-Week High Performance
- BigCommerce Experiences Remarkable Shifts Amid Market Pressures
- PRA Group Expands Credit Facilities for Future Growth
- Wesco International to Acquire Ascent, Boosting Data Center Services
- TCP Capital Corp Reaches New Low: Implications for Investors
- LendingTree Reports Significant Revenue Growth in Q3 Results
- Horizon Space Acquisition I Stock Hits New High on Merger News
- Fathom Holdings Strengthens Leadership at Verus Title
- Healthcare AI Acquisition Corp. Stock Achieves New Heights
- Big Tree Cloud Unveils Equity Incentive Plan for Growth
- ASE Technology Holdings: Future Growth Outlook and Innovations
- Uber Technologies Reports Exceptional Q3 2024 Results
- Key Stock Movements: Microsoft and Meta Face Market Challenges
- Altria Group Demonstrates Strong Growth Despite Market Pressures